STERIS plc
HealthcareNYSE:STE · New York Stock Exchange
+$0.70 today
Vol 0.49M · Avg 0.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.9%
avg 7.3%
ROIC
8.5%
avg 6.2%
ROA
7.3%
avg 4.5%
Analysis
ROE is currently the strongest return metric at 10.9% versus its period average of 7.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel A. Carestio | President, Chief Executive Officer & Director | $2.28M | — | 53 | $63,647.00 | 0.07% |
Andrew Xilas | Senior Vice President & GM of Dental | $1.44M | — | 61 | $6,347.00 | <0.01% |
John Adam Zangerle | Senior Vice President, General Counsel & Secretary | $943,792.00 | — | 59 | $36,678.00 | 0.04% |
Cary L. Majors | Senior Vice President & President of Healthcare | $861,813.00 | — | 51 | $17,405.00 | 0.02% |
Mary Clare Fraser | SVP & Chief Human Resources Officer | $725,668.00 | — | 56 | $13,716.00 | 0.01% |
Karen L. Burton | Senior Vice President, Chief Financial Officer & Chief Accounting Officer | — | — | 58 | $13,184.00 | 0.01% |
Lindsey McGowan | VP, Chief Compliance & Quality Officer | — | — | — | $5,985.00 | <0.01% |
Julie Winter | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Kenneth E. Kohler | Senior Vice President & GM of AST | — | — | 63 | $11,332.00 | 0.01% |
Julia K. Madsen | Senior Vice President & GM of Life Sciences | — | — | 61 | $12,257.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$12.89M
Net Sentiment
$12.89M
Net selling
Most Active
Tamaro Renato
4 transactions
1–10 of 16
Analysis
Insiders reported 0 buys worth $0.00 and 16 sells worth $12.89M over the last 12 months. That adds up to net selling of $12.89M. Tamaro Renato was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -16.9% | +17.9% (13yr)2 analysts |
| Revenue | N/A | N/A | +14.2% | +9.4% (13yr)2 analysts |
| Net Income | N/A | N/A | -11.5% | +20.9% (13yr)2 analysts |
| EBIT | N/A | N/A | -4.3% | +17.9% (13yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +14.2% over three years. Forward estimates point to Net Income at +20.9% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.57B
DexCom, Inc.
NASDAQ:DXCM
$28.78B
Koninklijke Philips N.V.
NYSE:PHG
$25.67B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.27B
Waters Corporation
NYSE:WAT
$23.15B
Quest Diagnostics Incorporated
NYSE:DGX
$22.46B
Labcorp Holdings Inc.
NYSE:LH
$21.67B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.14B
Smith & Nephew plc
NYSE:SNN
$12.98B
Insulet Corporation
NASDAQ:PODD
$10.36B
Who manages STE?
STERIS plc (STE) lists 10 active executives. The top listed executive is Andrew Xilas, Senior Vice President & GM of Dental.
Are STE insiders buying or selling?
Recent insider activity shows net buying of $40.74M.
Explore More
Continue the stock analysis
Jump to another research area for this company.